The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Single App knock-in mouse models of Alzheimer’s disease
Abstract
Experimental studies of Alzheimer's disease have largely depended on transgenic mice overexpressing amyloid precursor protein (APP). These mice, however, suffer from artificial phenotypes because, in addition to amyloid β peptide (Aβ), they overproduce other APP fragments. We generated knock-in mice that harbor Swedish and Beyreuther/Iberian mutations with and without the Arctic mutation in the APP gene. The mice showed typical Aβ pathology, neuroinflammation and memory impairment in an age-dependent manner.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We elected to use the AppNL-G-F knock-in mouse model for this study as it expresses App under its endogenous promoter in a physiological manner with regards to both cell type and amount, and avoids the issue of APP overexpression and abnormal expression patterns.”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [33]
In the citing paper
“AppNL-G-F mice [C57BL/6-App<tm3(NL-G-F)Tcs> (No.RBRC06344)] were provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan [33].”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [33]
In the citing paper
“we employed APPNLGF knock-in mice that express a humanized and triple-mutated APP in the endogenous App locus to circumvent transgenic mouse artifacts.”
From Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice (2024) · cites this paper as [34]
In the citing paper
“While novel APP knock-in models, such as APPNL, APPNL-F, or APPNL-G-F mice overproduce Aβ1–42 in the absence of potentially confounding APP overexpression [139], these mice still contain one or more independent FAD mutations, which might result in an abnormal Aβ conformation [140].”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [139]
In the citing paper
“By 6 months of age, App NL‐G‐F mice exhibit a substantial amyloid plaque burden in the brain”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“These were bred to the App NL‐G‐F AD‐like model to determine responses in the context of amyloid‐driven pathology (Saito et al. 2014).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“The App NL‐G‐F mice are characterized by progressive amyloid deposition from 2 months to cognitive decline by 6 months (Saito et al. 2014).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“The App NL‐G‐F knock‐in model, however, has physiological App expression levels, avoiding the overexpression artifacts found in other transgenic models”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“but is strongly biased toward very high Aβ42:40 ratios (~10–100:1) because of the familial mutations”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“In AppNL-G-F mice, which harbor all three mutations, Aβ amyloidosis is aggressive, and neuroinflammation is observed in subcortical structures as well as cortical regions [10–12].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“By contrast, AppNL mice that carry only the Swedish mutation produce significantly higher levels of Aβ40 and Aβ42 without overt AD-related brain pathology such as extracellular Aβ plaques or neuroinflammation [10, 11, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“alternative mouse models have been generated via knock-in (KI) of a humanized Aβ sequences harboring familial AD mutations (Swedish (NL), Beyreuther/Iberian (F), and Arctic (G)) in order to model Aβ amyloidosis without non-physiological overexpression of APP [10].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“By contrast, AppNL mice that carry only the Swedish mutation produce significantly higher levels of Aβ40 and Aβ42 without overt AD-related brain pathology such as extracellular Aβ plaques or neuroinflammation [10, 11, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“To overcome these issues, KI mouse models with familial AD mutations have been generated [10, 24, 31, 32].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“despite overproducing human Aβ40 and Aβ42 in their brains [10, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“These results are consistent with recent studies reporting negligible cognitive deficits and the lack of Aβ plaque formation in AppNL/NL mice (Fig. 6) [10, 11, 13, 14, 24].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“Both models express human APP at physiological levels.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“The AppNL-G-F and AppNL-F show neuropathology and hippocampus-dependent cognitive impairments at 6 or 18 months, respectively.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“Our result in female mice is consistent with the cognitive phenotype in the Y maze reported in this genotype25,42.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“Human APP knockin (KI) models develop robust Aβ pathology, yet do not exhibit artifacts associated with APP over-expression, such as elevated levels of APP cleavage products (Saito et al., 2014).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These studies all suffer because they exhibit artifacts arising from the over-expression APP (WT or mutant) and in some cases mutant presenilins (Balducci and Forloni, 2011; Saito et al., 2014; Sasaguri et al., 2017).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“Human MAPT knock-in models have also been developed, and these models produce tau pathology, but only very late in the murine life span (~15 months) (Saito et al., 2014; Sakakibara et al., 2018; Sasaguri et al., 2022).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“However, over-expressing APP and presenilin 1 cause effect resulting from the over-expression that are unrelated to the disease process (Saito et al., 2014; Sakakibara et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These mice develop robust plaque pathology beginning as early as 3 months of age, however they develop little tau pathology and little neurodegeneration (Saito et al., 2014; Sakakibara et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These patterns of labeling or Aβ and MAPT are consistent with prior studies of APPNL-G-F and P301S MAPT mice (Yoshiyama et al., 2007; Saito et al., 2014; Sasaguri et al., 2017; Apicco et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“As expected,15 22-month-old AppNL-G-F mice had robust AD-related pathology, including amyloid deposition and neuroinflammation (Figures 1C and 1D).”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“As suggested,15,20 App KI mice may model pre-clinical stages of AD, characterized by progressive amyloidosis and gliosis without prominent cognitive deterioration, tau pathology, or neurodegeneration.”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“Humanized App knockin (KI) and APP transgenic mouse models mimic certain aspects of AD pathogenesis, including progressive amyloidosis, gliosis, and neuroinflammation, as well as network hyperexcitability and cognitive impairment, albeit to different degrees of severity across models and paradigms.15-27”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“Whereas plaque deposition only increases by less than twofold between 9 and 12 months of age, it increases tenfold between 12 and 18 months (Saito et al., 2014).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“By contrast, NHE6 ablation led to glial activation and decreased plaque load in ApoeAPOE4 (Sullivan et al., 1997) and AppNL-F (Saito et al., 2014) double knockin mice.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“The AppNL-F mouse model used in our study develops plaques at 12 months (Saito et al., 2014) in the presence of murine ApoE.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“In AppNL-F mice, plaques can be identified as early as 9 months of age.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“These mice, however, do not show cognitive impairments in spatial learning tests like Morris water maze (Saito et al., 2014) (own unpublished observations).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“We show in a well-studied App knock-in mouse model (Saito et al. , 2014) the gradual establishment of a multicellular co-expressed gene response encompassing 57 Plaque-Induced Genes or PIGs in the microenvironments of amyloid plaques (Figure 5).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Saito et al., 2014
In the citing paper
“App NL-G-F knock-in (Saito et al., 2014) mice express Swedish (KM670/671NL), Beyreuther/Iberian (I716F), and Arctic (E693G) mutations in the App gene under the endogenous promoter on the C57Bl/6J background.”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Saito et al., 2014
In the citing paper
“AD mice, in which APP with a humanised Aβ region containing 3 AD-related mutations (APPNL-G-F) is knocked in (49), to avoid artefacts associated with over-expressing APP, were crossed with NG2-DsRed mice in which pericytes express DsRed (19).”
From Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes (2019) · cites this paper as [49]
In the citing paper
“In contrast, knock-in of Swedish and Iberian mutations results in plaque development beginning at 6 months, and gliosis, synaptic alterations and memory impairment from 18 months [129].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
In the citing paper
“Additional knock-in of the Arctic mutation into these mice results in more rapid pathology development including plaque development beginning at 2 months that is more widespread throughout the brain and memory impairment from 6 months [129].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
In the citing paper
“In contrast, initial studies show that more physiological knock-in mouse models develop cognitive impairment many months after plaque development [129], which is more similar to humans.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
Citations
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587
Self-citationAβ Secretion and Plaque Formation Depend on Autophagy
Nilsson, P., Loganathan, K., Sekiguchi, M., Matsuba, Y., Hui, K., Tsubuki, S., Tanaka, M., Iwata, N., Saito, T., & Saido, T. C. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.042 · Cited by 459
Self-citationSarnyai, Z., Sibille, E. L., Pavlides, C., Fenster, R. J., McEwen, B. S., & Tóth, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14731 · Cited by 396
Cited by
Sorted by citations
Items 501–600 of 1,333
Mehla, J., Deibel, S. H., Karem, H., Hossain, S., Lacoursiere, S. G., Sutherland, R. J., Mohajerani, M. H., & McDonald, R. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01085-6 · Cited by 22
Increase in Tau Pathology in P290S Mapt Knock-In Mice Crossed with App NL-G-F Mice
Huang, M., Macdonald, J., Lavenir, I., Chen, R., Craxton, M., Slavik-Smith, E., Davies, S. W., & Goedert, M. (2022) · eneuro · doi:10.1523/eneuro.0247-22.2022 · Cited by 19
Akasaka, T., Watanabe, H., & Ono, M. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.136132 · Cited by 19
Raber, J., Perez, R., Torres, E. R. S., Krenik, D., Boutros, S. W., Patel, E. M., Chlebowski, A. C., Torres, E. R., Perveen, Z., Penn, A. L., et al. (2021) · Environmental Health Perspectives · doi:10.1289/ehp8428 · Cited by 19
Funane, T., Jun, H., Sutoko, S., Saido, T. C., Kandori, A., & Igarashi, K. M. (2022) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2022.955178 · Cited by 19
Self-citationSato, W., Watanabe‐Takahashi, M., Murata, T., Utsunomiya‐Tate, N., Motoyama, J., Anzai, M., Ishihara, S., Nishioka, N., Uchiyama, H., Togashi, J., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04771-9 · Cited by 19
Self-citationCasares, N., Alfaro, M., Cuadrado‐Tejedor, M., Lasarte-Cía, A., Navarro, F. C., Vivas, I., Espelosin, M., Cartas‐Cejudo, P., Fernández‐Irigoyen, J., Santamaría, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130044 · Cited by 20
Progressive sleep disturbance in various transgenic mouse models of Alzheimer’s disease
Drew, V. J., Wang, C., & Kim, T. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1119810 · Cited by 19
Rakovskaya, A., Erofeev, A., Vinokurov, E. K., Pchitskaya, E. I., Dahl, R. S., & Борисович, Б. И. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813973 · Cited by 20
Sex‐dependent cholinergic effects on amyloid pathology: A translational study
German‐Castelan, L., Shanks, H. R. C., Gros, R., Saito, T., Saido, T. C., Saksida, L. M., Bussey, T. J., Prado, M. A. M., Schmitz, T. W., Prado, V. F., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13481 · Cited by 22
Self-citationRodent Models of Alzheimer’s Disease: Past Misconceptions and Future Prospects
Collins, H. M., & Greenfield, S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116222 · Cited by 21
Zhang, C., Aida, M., Saggu, S., Yu, H., Zhou, L., Rehman, H., Jiao, K., Liu, R., Wang, L., & Wang, Q. (2024) · Science Advances · doi:10.1126/sciadv.adn8709 · Cited by 19
Experimental Pharmacology in Transgenic Rodent Models of Alzheimer’s Disease
Cuello, A. C., Hall, H., & Carmo, S. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00189 · Cited by 21
Obata, Y., Murakami, K., Kawase, T., Hirose, K., Izuo, N., Shimizu, T., & Irie, K. (2020) · ACS Omega · doi:10.1021/acsomega.0c02134 · Cited by 19
Aldabbagh, Y., Islam, A., Zhang, W., Whiting, P. J., & Ali, A. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.822499 · Cited by 20
PET Imaging in Preclinical Anti-Aβ Drug Development
Syvänen, S., Meier, S. R., Roshanbin, S., Xiong, M., Faresjö, R., Gustavsson, T., Bonvicini, G., Schlein, E., Aguilar, X., Julku, U. H., et al. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03277-z · Cited by 20
Impairment of ciliary dynamics in an APP knock-in mouse model of Alzheimer’s disease
Kobayashi, Y., Kohbuchi, S., Koganezawa, N., Sekino, Y., Shirao, T., Saido, T. C., Saito, T., & Saito, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.050 · Cited by 18
Self-citationNi, R. (2021) · Pharmaceuticals · doi:10.3390/ph14111179 · Cited by 18
Mehla, J., Deibel, S. H., Karem, H., Hong, N. S., Hossain, S. R., Lacoursiere, S. G., Sutherland, R. J., Mohajerani, M. H., & McDonald, R. J. (2023) · Communications Biology · doi:10.1038/s42003-023-05506-6 · Cited by 18
Furuta, M., Arii, S., Umeda, H., Matsukawa, R., Shizu, K., Kaji, H., Kawashima, S. A., Hori, Y., Tomita, T., Sohma, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202401346 · Cited by 18
Mandino, F., Shen, X., Desrosiers-Grégoire, G., O’Connor, D. A., Mukherjee, B., Owens, A., Qu, A., Onofrey, J. A., Papademetris, X., Chakravarty, M. M., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02779-z · Cited by 19
Navigating Alzheimer’s Disease Mouse Models: Age-Related Pathology and Cognitive Deficits
Plano, L. M. D., Saitta, A., Oddo, S., & Caccamo, A. (2024) · Biomolecules · doi:10.3390/biom14111405 · Cited by 22
Andrade‐Talavera, Y., Chen, G., Kurudenkandy, F. R., Johansson, J., & Fisahn, A. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105514 · Cited by 18
Alzheimer’s Disease: Current Perspectives and Advances in Physiological Modeling
Boder, E. J., & Banerjee, I. A. (2021) · Bioengineering · doi:10.3390/bioengineering8120211 · Cited by 18
Sinnige, T., Stroobants, K., Dobson, C. M., & Vendruscolo, M. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000025 · Cited by 18
Lysosomal Dysregulation in the Murine App Model of Alzheimer’s Disease
Whyte, L. S., Hassiotis, S., Hattersley, K. J., Hemsley, K. M., Hopwood, J. J., Lau, A. A., & Sargeant, T. J. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2019.12.042 · Cited by 19
Improving Mouse Models for Dementia. Are All the Effects in Tau Mouse Models Due to Overexpression?Preprint
Joel, Z., Izquierdo, P., Salih, D. A. M., Richardson, J. C., Cummings, D. M., & Edwards, F. A. (2018) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2018.83.037531 · Cited by 18
Perdok, A., Acker, Z. P. V., Vrancx, C., Sannerud, R., Vorsters, I., Verrengia, A., Callaerts‐Vegh, Z., Creemers, E., Fernández, S. G., D’hauw, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54777-y · Cited by 18
Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils
Etani, H., Takatori, S., Wang, W., Omi, J., Amiya, Y., Akahori, A., Watanabe, H., Sonn, I., Okano, H., Hara, N., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01891-8 · Cited by 16
Self-citationCell models for Down syndrome-Alzheimer’s disease research
Wu, Y., West, N. R., Bhattacharyya, A., & Wiseman, F. K. (2022) · Neuronal Signaling · doi:10.1042/ns20210054 · Cited by 17
Hippocampal functional connectivity across age in an App knock-in mouse model of Alzheimer's disease
Morrissey, Z. D., Gao, J., Zhan, L., Li, W., Fortel, I., Saido, T. C., Saito, T., Bakker, A., Mackin, S. R., Ajilore, O., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1085989 · Cited by 18
Self-citationKilian, J., Mejias‐Ortega, M., Hsu, H.-W., Herman, D. A., Vidal, J., Arechavala, R. J., Renusch, S. R., Dalal, H., Hasen, I., Ting, A., et al. (2023) · Toxicological Sciences · doi:10.1093/toxsci/kfad036 · Cited by 18
Self-citationGenetic diversity promotes resilience in a mouse model of Alzheimer's disease
Soni, N., Hohsfield, L. A., Tran, K. M., Kawauchi, S., Walker, A., Javonillo, D. I., Phan, J., Matheos, D. P., Cunha, C. D., Uyar, A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13753 · Cited by 17
Schlein, E., Andersson, K. G., Dallas, T. D., Syvänen, S., & Sehlin, D. (2024) · mAbs · doi:10.1080/19420862.2024.2339337 · Cited by 18
Bignante, E. A., Ponce, N. E., Heredia, F., Musso, J., Krawczyk, M. C., Millan, J., Pigino, G. F., Inestrosa, N. C., Boccia, M. M., & Lorenzo, A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.013 · Cited by 17
Mehla, J., Deibel, S. H., Faraji, J., Saito, T., Saido, T. C., Mohajerani, M. H., & McDonald, R. J. (2018) · Hippocampus · doi:10.1002/hipo.22999 · Cited by 17
Self-citationTezel, G., Timur, S. S., Bozkurt, İ., Türkoğlu, Ö. F., Eroğlu, İ., Nemutlu, E., Öner, L., & Eroğlu, H. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00511 · Cited by 17
Schedin‐Weiss, S., Nilsson, P., Matton, A., Axenhus, M., Sekiguchi, M., Saito, T., Winblad, B. G., Saido, T. C., & Tjernberg, L. O. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200028 · Cited by 17
Self-citationJafari, Z., Afrashteh, N., Kolb, B. E., & Mohajerani, M. H. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114413 · Cited by 17
Izuo, N., Murakami, K., Fujihara, Y., Maeda, M., Saito, T., Saido, T. C., Irie, K., & Shimizu, T. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.131 · Cited by 17
Self-citationIslam, A., Saito, T., Saido, T., & Ali, A. B. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.03.001 · Cited by 17
Self-citationWu, Y., Mumford, P., Noy, S., Cleverley, K., Mrzyglod, A., Luo, D., van Dalen, F., Verdoes, M., Fisher, E. M. C., & Wiseman, F. K. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01632-8 · Cited by 16
Human stem cell transplantation models of Alzheimer’s disease
Ifediora, N., Canoll, P., & Hargus, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1354164 · Cited by 18
Braun, D. J., Dimayuga, E. R., Morganti, J. M., & Eldik, L. J. V. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01938-7 · Cited by 16
Vignon, A., Salvador-Prince, L., Lehmann, S., Perrier, V., & Torrent, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168769 · Cited by 17
Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer’s disease
Kaneshiro, N., Komai, M., Imaoka, R., Ikeda, A., Kamikubo, Y., Saito, T., Saido, T. C., Tomita, T., Hashimoto, T., Iwatsubo, T., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103869 · Cited by 16
Self-citationBorcuk, C., Héraud, C., Herbeaux, K., Diringer, M., Panzer, É., Scuto, J., Hashimoto, S., Saido, T. C., Saito, T., Goutagny, R., et al. (2022) · Aging Brain · doi:10.1016/j.nbas.2022.100042 · Cited by 18
Self-citationHonda, K., Saito, Y., Saito, H., Toyoda, M., Abe, R., Saito, T., Saido, T. C., Michikawa, M., Taru, H., Sobu, Y., et al. (2022) · SSRN Electronic Journal · doi:10.1016/j.neurobiolaging.2022.12.003 · Cited by 16
Self-citationJiang, L., Roberts, R., Wong, M., Zhang, L., Webber, C. J., Libera, J., Wang, Z., Kilci, A., Jenkins, M., Ortiz, A. R., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1372297 · Cited by 15
Self-citationResearch models to study lewy body dementia
Boschen, S. L., Mukerjee, A. A., Faroqi, A. H., Rabichow, B. E., & Fryer, J. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00837-w · Cited by 16
Universal Artificial Urinary Biomarker Probe Enabled by an Aptamer–DNAzyme–Nanozyme Construct
Xiao, Y., Wong, J. H., Gao, N., Barron, A. M., Stanley, C. V., Than, A., Zheng, L., Ling, T., Li, D., & Chen, P. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c02356 · Cited by 15
Vandermeulen, L., Geric, I., Fumagalli, L., Kreir, M., Lu, A., Nonneman, A., Premereur, J., Wolfs, L., Policarpo, R., Fattorelli, N., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00725-9 · Cited by 16
Strategies to dissect microglia-synaptic interactions during aging and in Alzheimer's disease
Heuer, S. E., Bloss, E. B., & Howell, G. R. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109987 · Cited by 16
The Inflammation-Induced Dysregulation of Reelin Homeostasis Hypothesis of Alzheimer’s Disease
Reive, B. S., Lau, V. Z., Sánchez-Lafuente, C. L., Henri‐Bhargava, A., Kalynchuk, L. E., Tremblay, M., & Caruncho, H. J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240088 · Cited by 15
PET imaging of TREM2 in amyloid-beta induced neuroinflammation
Dahlén, A. D., Roshanbin, S., Aguilar, X., Bucher, N. M., van den Broek, S. L., Sehlin, D., & Syvänen, S. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07358-0 · Cited by 15
Endogenous murine Aβ increases amyloid deposition in APP23 but not in APPPS1 transgenic mice
Mahler, J., Morales‐Corraliza, J., Stolz, J., Skodras, A., Radde, R., Duma, C. C., Eisele, Y. S., Mazzella, M. J., Wong, H. K. A., Klunk, W. E., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.03.011 · Cited by 15
Pravin, N., Kumar, R., Tripathi, S., Kumar, P., Mohite, G. M., Navalkar, A., Panigrahi, R., Singh, N., Gadhe, L. G., Manchanda, S., et al. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15138 · Cited by 15
Self-citationA potential defense mechanism against amyloid deposition in cerebellum
Shahnur, A., Nakano, M., Ishihara, S., Kakuda, N., Miyasaka, T., Uchiyama, H., Shirai, Y., Moniruzzaman, M., Saito, T., Saido, T. C., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.12.036 · Cited by 15
Self-citationCope, Z. A., Murai, T., & Rizzo, S. J. S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.805063 · Cited by 18
Quan, Z.-J., Li, S.-A., Yang, Z.-X., Zhao, J.-J., Li, G., Zhang, F., Wen, W., Cheng, T., & Zhang, X. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.06.002 · Cited by 17
A CHCHD6–APP axis connects amyloid and mitochondrial pathology in Alzheimer’s disease
Shang, Y., Sun, X., Chen, X., Wang, Q., Wang, E. J., Miller, E., Xu, R., Pieper, A. A., & Qi, X. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02499-0 · Cited by 15
Hou, X., Jiang, H., Liu, T., Yan, J., Zhang, F., Zhang, X., Zhao, J., Mu, X., & Jiang, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114455 · Cited by 16
Masuda, A., Kobayashi, Y., & Itohara, S. (2018) · Journal of Visualized Experiments · doi:10.3791/58009 · Cited by 15
Self-citationSIRT1 Regulates Tau Expression and Tau Synaptic Pathology
Yin, X., Zhou, Z., Qiu, Y., Fan, X., Zhao, C., Bao, J., Liu, C., Liu, F., & Qian, W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215118 · Cited by 15
Sinnige, T., Stroobants, K., Dobson, C. M., & Vendruscolo, M. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000104 · Cited by 15
Niidome, T., Ishikawa, Y., Ogawa, T., Nakagawa, M., & Nakamura, Y. (2024) · Folia Pharmacologica Japonica · doi:10.1254/fpj.24005 · Cited by 14
A decade progress in the phenotyping of App knock-in mouse model of Alzheimer’s disease
Manabe, T., & Saito, T. (2025) · Neuroscience Research · doi:10.1016/j.neures.2025.104959 · Cited by 13
Self-citationAghaizu, N. D., Jolly, S., Samra, S. K., Kalmár, B., Craessaerts, K., Greensmith, L., Salinas, P. C., Strooper, B. D., & Whiting, P. J. (2023) · eNeuro · doi:10.1523/eneuro.0306-22.2022 · Cited by 14
Role of sex hormones in neuroinflammation in Alzheimer's disease
Maekawa, K., & Yamanaka, K. (2023) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12744 · Cited by 14
Sánchez-Puebla, L., López‐Cuenca, I., Salobrar‐García, E., Ramirez, A. I., Fernández‐Albarral, J. A., Matamoros, J. A., Elvira‐Hurtado, L., Salazar, J. J., Ramirez, J. M., & de Hoz, R. (2024) · Biomedicines · doi:10.3390/biomedicines12030528 · Cited by 14
Zhang, W., Liu, T., Li, J., Singh, J., Chan, A., Islam, A., Petrache, A. L., Peng, Y., Harvey, K., & Ali, A. B. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16441 · Cited by 15
Brain Microvascular Pericyte Pathology Linking Alzheimer's Disease to Diabetes
El‐Ghazawi, K., Eyo, U. B., & Peirce, S. M. (2024) · Microcirculation · doi:10.1111/micc.12877 · Cited by 14
Min, J.-H., Sarlus, H., Oasa, S., & Harris, R. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-74359-8 · Cited by 14
Chandra, S., & Vassar, R. J. (2024) · Immunological Reviews · doi:10.1111/imr.13412 · Cited by 17
Longitudinal characterization reveals behavioral impairments in aged APP knock in mouse models
Blackmer‐Raynolds, L., Lipson, L. D., Fraccaroli, I., Krout, I. N., Chang, J., & Sampson, T. R. (2025) · Scientific Reports · doi:10.1038/s41598-025-89051-8 · Cited by 14
Yeapuri, P., Machhi, J., Foster, E. G., Kadry, R., Bhattarai, S., Lu, Y., Sil, S., Sapkota, R., Srivastava, S., Kumar, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70084 · Cited by 15
Liu, X., Zhou, Q., Zhang, J.-H., Wang, K., Saito, T., Saido, T. C., Wang, X., Gao, X., & Azuma, K. (2021) · Cells · doi:10.3390/cells10113261 · Cited by 15
Self-citationBarthelson, K., Newman, M., & Lardelli, M. T. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049187 · Cited by 14
Lysosomal gene Hexb displays haploinsufficiency in a knock-in mouse model of Alzheimer’s disease
Whyte, L. S., Fourrier, C., Hassiotis, S., Lau, A. A., Trim, P. J., Hein, L. K., Hattersley, K. J., Bensalem, J., Hopwood, J. J., Hemsley, K. M., et al. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.01.004 · Cited by 14
Propolis Promotes Memantine-Dependent Rescue of Cognitive Deficits in APP-KI Mice
Moriguchi, S., Inagaki, R., Saito, T., Saido, T. C., & Fukunaga, K. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02876-6 · Cited by 14
Self-citationScott, C. A. M.-G., Pelkey, K. A., Caccavano, A., Abebe, D. T., Lai, M., Black, K. N., Brown, N. D., Trevelyan, A. J., & McBain, C. J. (2022) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2022.857608 · Cited by 14
Tun, X., Wang, E. J., Gao, Z., Lundberg, K. C., Xu, R., & Hu, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065697 · Cited by 14
Critical thinking of Alzheimer’s transgenic mouse model: current research and future perspective
Li, X., Quan, M., Wei, Y., Wang, W., Xu, L., Wang, Q., & Jia, J. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2357-x · Cited by 14
Srinivasan, S., Kancheva, D., Ren, S. D., Saito, T., Jans, M., Boone, F., Vandendriessche, C., Paesmans, I., Maurin, H., Vandenbroucke, R. E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1323409 · Cited by 16
Self-citationAn astrocyte-microglia MFG-E8 axis promotes synapse engulfment in early amyloid pathology
Sokolova, D., Puletti, F., Ghansah, S. A., Georgiades, T., Zheng, Y., Wu, L., Schepper, S. D., Lange, J., Ferreira, L. S. S., Sierksma, A., et al. (2026) · Neuron · doi:10.1101/2024.08.31.606944 · Cited by 15
King, M. W., Jacob, S. M., Sharma, A., Lawrence, J. H., & Musiek, E. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70885 · Cited by 13
Regional contributions of D-serine to Alzheimer’s disease pathology in male AppNL–G–F/NL–G–F mice
Ni, X., Inoue, R., Wu, Y., Yoshida, T., Yaku, K., Nakagawa, T., Saito, T., Saido, T. C., Takao, K., & Mori, H. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1211067 · Cited by 13
Self-citationQu, W., Lam, M., McInvale, J. J., Mares, J. A., Kwon, S. H., Humala, N., Mahajan, A., Nguyen, T. T. T., Jakubiak, K. A., Mun, J.-Y., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02755-5 · Cited by 13
MouseGoggles: an immersive virtual reality headset for mouse neuroscience and behavior
Isaacson, M. D., Chang, H., Berkowitz, L. E., Zirkel, R. T., Park, Y. A., Hu, D., Ellwood, I. T., & Schaffer, C. B. (2024) · Nature Methods · doi:10.1038/s41592-024-02540-y · Cited by 13
Morito, T., Qi, M., Kamano, N., Sasaguri, H., Bez, S., Foiani, M. S., Duff, K., Benner, S., Endo, T., Hama, H., et al. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2025.101024 · Cited by 14
Self-citationDeibel, S. H., Weishaupt, N., Regis, A. M., Hong, N. S., Keeley, R. J., Balog, R. J., Bye, C. M., Himmler, S. M., Whitehead, S. N., & McDonald, R. J. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.033 · Cited by 13
Nieraad, H., de Bruin, N. M. W. J., Arne, O., Hofmann, M. C. J., Schmidt, M., Saito, T., Saido, T. C., Gurke, R., Schmidt, D., Till, U., et al. (2020) · Nutrients · doi:10.3390/nu12113248 · Cited by 13
Self-citationYoshimatsu, S., Seki, F., Okahara, J., Watanabe, H., Sasaguri, H., Haga, Y., Hata, J., Sanosaka, T., Inoue, T., Mineshige, T., et al. (2022) · Neuroscience Research · doi:10.1016/j.neures.2022.08.008 · Cited by 13
Self-citationGaunt, J. R., Zainolabidin, N., Yip, A. K. K., Tan, J. M., Low, A. Y. T., Chen, A. I., & Ch’ng, T. H. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02913-8 · Cited by 12
Zhao, L., Chen, M.-W., Qian, Y., Yang, Q., Ge, Y., Chen, H., & Qiu, Y. L. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.04.007 · Cited by 13
Salivary Aβ Secretion and Altered Oral Microbiome in Mouse Models of AD
Floden, A. M., Sohrabi, M., Nookala, S., Cao, J., & Combs, C. K. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210119151952 · Cited by 13
Andrade‐Talavera, Y., Balleza‐Tapia, H., Dolz-Gaitón, P., Chen, G., Johansson, J., & Fisahn, A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01332-8 · Cited by 13
Gulbranson, D. R., Ho, K., Yu, G.-Q., Yu, X., Das, M. M., Shao, E., Kim, D., Zhang, W. J., Choudhary, K., Thomas, R., et al. (2021) · eNeuro · doi:10.1523/eneuro.0089-21.2021 · Cited by 14
Tok, S., Maurin, H., Delay, C., Crauwels, D., Manyakov, N. V., der Elst, W. V., Moechars, D., & Drinkenburg, W. H. I. M. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01393-w · Cited by 14
Choi, D., Murali, S., Kwon, W., Woo, J., Song, E. C., Ko, Y., Sardar, D., Lozzi, B., Cheng, Y.-T., Williamson, M. R., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02115-w · Cited by 12
Metadata
- Authors
- Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C.
- Affiliations
- RIKEN Center for Brain Science (JP)
- Corresponding author
- Saido, Takaomi C
- Venue
- Nature Neuroscience
- Published
- 2014-04-13
- Volume
- 17
- Issue
- 5
- Pages
- 661-663
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2090620788
- Cited by
- 1,366
- References
- 26
- Citations by year
- 2026: 159 · 2025: 164 · 2024: 209 · 2023: 167 · 2022: 157 · 2021: 155 · 2020: 92 · 2019: 73 · 2018: 64 · 2017: 49 · 2016: 37 · 2015: 24 · 2014: 13
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23680039, 26290019)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, knock-in mice, amyloid precursor protein, APP mutations, Swedish mutation, Arctic mutation, amyloid-beta pathology, neuroinflammation, memory impairment, age-dependent phenotype
- MeSH terms
- Age Factors, Alzheimer Disease, Analysis of Variance, Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Humans, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Maze Learning, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
